As of 2025-06-21, the Intrinsic Value of Oramed Pharmaceuticals Inc (ORMP) is -3.46 USD. This ORMP valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.13 USD, the upside of Oramed Pharmaceuticals Inc is -262.27%.
Based on its market price of 2.13 USD and our intrinsic valuation, Oramed Pharmaceuticals Inc (ORMP) is overvalued by 262.27%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -3.46 - -3.46 | -3.46 | -262.27% |
| P/E | (12.83) - (12.25) | (12.84) | -702.8% |
| DDM - Stable | (5.42) - (21.60) | (13.51) | -734.2% |
| DDM - Multi | (3.21) - (10.40) | (4.96) | -332.7% |
| Market Cap (mil) | 87.01 |
| Beta | 0.37 |
| Outstanding shares (mil) | 40.85 |
| Enterprise Value (mil) | 12.49 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.91% |
| Cost of Debt | 5.00% |
| WACC | 6.79% |